Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

Novo Nordisk remains the stronger obesity-care investment case, with GLP-1 market share at 54.6% globally and multiple label expansions, but 2026 sales and EPS are still expected to decline 2.45% and 13.64%, respectively. Viking Therapeutics has promising VK2735 data and is advancing VK3019, but it remains a clinical-stage biotech with no approved products and widening 2026–2027 loss estimates. The article is largely comparative rather than event-driven, though ongoing regulatory approvals, launches, and competitive pressure from Eli Lilly remain important stock-specific catalysts.

Analysis

The market is starting to separate “scale winners” from “future optionality” in obesity. NVO still owns the commercial flywheel, but the key second-order issue is margin compression: as the category broadens, payer leverage rises faster than volume, so revenue can grow while EPS stalls or declines. That makes NVO less of a pure growth story and more of a cash-flow defense trade until management proves it can offset pricing pressure with mix, international penetration, and higher-value indications.

LLY is the clearest structural winner from the competitive set because it now has both injectable and oral exposure, which should let it attack the two most profitable failure modes for competitors: needle aversion and adherence. The real incremental risk for NVO is not just share loss, but a shift in prescriber behavior toward “good enough” efficacy with better convenience, which can compress the premium commanded by semaglutide across the franchise. If oral adoption accelerates, the category may expand faster than feared while still redistributing economics toward the company with the broader convenience stack.

VKTX remains a classic long-duration catalyst trade, not a fundamental investment yet. The market is implicitly assigning value to late-stage success before the maintenance data and phase III readouts, which creates a sharp binary setup: positive durability data in 3Q26 could rerate the stock, but the path to monetization is still 18-24 months away. The hidden risk is that any efficacy disappointment would hit harder than expected because the obesity space has become less forgiving on differentiation and more sensitive to tolerability, convenience, and payer access.

Consensus appears to underweight how much optionality in obesity now depends on combination therapy and life-cycle management rather than first-wave efficacy alone. That favors diversified incumbents with manufacturing, distribution, and label-expansion leverage, while leaving single-asset biotechs exposed to a higher bar for “best in class.” On valuation, VKTX’s book multiple is not just expensive versus NVO; it reflects pricing in future pipeline success before the market has evidence that its maintenance dosing can preserve weight loss in a commercially viable regimen.

Key Decisions for Investors

• Stay long NVO only as a defensive compounder, not a momentum long; target a 6-12 month hold and use strength to trim into any rerating above the level justified by declining 2026 EPS, since price pressure and competition can cap upside.
• Initiate/maintain long LLY vs short NVO pair trade over the next 3-9 months; LLY has the cleaner operating leverage from oral plus injectable breadth, while NVO still faces the heavier burden of defending share and margins.
• Trade VKTX as a catalyst optionality name: buy call spreads into 2Q26/3Q26 maintenance-data window and plan to monetize into the readout, because the stock likely over-discounts a positive outcome before clinical proof arrives.
• For event-driven downside protection, hedge any VKTX long with puts into the phase III data window in 2027; the binary downside is larger than the upside if durability or tolerability disappoints.
• If seeking relative value in obesity, avoid outright long VKTX versus NVO/LLY until phase III de-risks; the better risk/reward is expressed through options rather than cash equity given the 18-24 month commercialization gap.